{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:01:43Z","timestamp":1787583703090,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: A quadrivalent HPV vaccine (BPV) has been developed to prevent diseases caused by HPV types 6, 11, 16, and 18 for the first time in Iran. The BPV is composed of the papillomavirus major capsid protein L1, which serves as the primary target in the design of the prophylactic HPV vaccines. To enhance immunogenicity, BPV was formulated with an amorphous aluminum hydroxy phosphate sulfate adjuvant. Methods: The immunogenicity and safety of BPV were assessed through analyses of both humoral and cell-mediated immunity, single and repeated doses, and reproductive effects using animal models. Results: Acute toxicity assessments showed no abnormalities in ophthalmic examinations, biochemical profiles, hematological parameters, and gross pathology findings. Additionally, no mortality or abnormal clinical signs were observed during a 90-day repeated-dose toxicity study. While some inflammatory reactions were noted at the injection sites and in the liver tissues of BPV-treated groups, these reactions were resolved by day 90 after the initial BPV administration. Furthermore, no signs of toxicity were detected in F1 offspring, and no adverse effects were identified in maternal reproductive performance, fertility, or hematological or biochemical parameters throughout the study duration. The BPV candidate successfully induced T-cell proliferation and increased the proportions of CD3+ CD4+ and CD3+ CD8+ T cells. It also stimulated the secretion of both interferon gamma (IFN-\u03b3) and interleukin-4 (IL-4) cytokines in splenocytes isolated from animal models after the third dose. Moreover, anti-HPV L1 IgG antibody production was confirmed on day 14 after administration of each of the three BPV vaccine doses. Conclusions: The findings suggest that BPV is a vaccine candidate that stimulates both cellular and humoral immunity and demonstrate its safety profile in animal models.<\/jats:p>","DOI":"10.3390\/vaccines14010066","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:28:57Z","timestamp":1767626937000},"page":"66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical Assessment of a New Virus-like Particle-Based Quadrivalent Human Papillomavirus Vaccine in Animal Models"],"prefix":"10.3390","volume":"14","author":[{"given":"Hajar","family":"Mohammadi Barzelighi","sequence":"first","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Naderi Saffar","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Pakatchian","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Taqavian","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Javadimehr","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansooreh","family":"Safaeian","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Abbaszadeh","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biosunpharmed Company, Tehran 1436935359, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Jalili","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Faculty of New Sciences and Technologies, University of Tehran, Tehran 1417935840, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_3","first-page":"720","article-title":"Cervical cancer: Epidemiology, risk factors and screening","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Choi, S., Ismail, A., Pappas-Gogos, G., and Boussios, S. (2023). HPV and cervical cancer: A review of epidemiology and screening uptake in the UK. Pathogens, 12.","DOI":"10.3390\/pathogens12020298"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.31557\/APJCP.2018.19.12.3361","article-title":"Phylogeny and classification of human papillomavirus (HPV) 16 and HPV18 variants based on E6 and L1 genes in Tunisian women with cervical lesions","volume":"19","author":"Satouri","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_6","unstructured":"Meites, E., Gee, J., Unger, E., and Lauri, M. (2024). Human papillomavirus. Pink Book, Health Care Providers, Public Health Foundation. [14th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_8","unstructured":"Word Health Organization (2022). Human papillomavirus vaccines: WHO position paper. Wkly. Epidemiol. Rec., 97, 645\u2013672. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: Passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"ref_10","unstructured":"Word Health Organization (2007). International Agency for Research on Cancer and IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Williamson, A.-L. (2023). Recent developments in human papillomavirus (HPV) vaccinology. Viruses, 15.","DOI":"10.3390\/v15071440"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1016\/j.vaccine.2012.04.079","article-title":"Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine CervarixTM in mice","volume":"30","author":"Han","year":"2012","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tariq, H., Batool, S., Asif, S., Ali, M., and Abbasi, B.H. (2022). Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.790121"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00553","DOI":"10.34172\/jrhs.2022.88","article-title":"Prevalence of human papillomavirus genotypes in Tehran, Iran","volume":"22","author":"Shalchimanesh","year":"2022","journal-title":"J. Res. Health Sci."},{"key":"ref_16","first-page":"19","article-title":"The prevalence of HPV genotypes in Iranian population: An update","volume":"14","author":"Kesheh","year":"2019","journal-title":"Iran J. Pathol."},{"key":"ref_17","unstructured":"Gardasil, S.T. (2020, June 24). 9. Human Papillomavirus 9-Valent Vaccine (Recombinant, Adsorbed). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gardasil-9-epar-product-information_it.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41684-021-00871-3","article-title":"Guideline for the care and use of laboratory animals in Iran","volume":"50","author":"Sadighi","year":"2021","journal-title":"Lab Anim."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jat.3131","article-title":"Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16\/18 vaccine in rabbits and rats","volume":"35","author":"Segal","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/14760584.2019.1704261","article-title":"HPV vaccines: Alternative dosage schedules","volume":"18","author":"Stanley","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1016\/j.vaccine.2018.08.071","article-title":"Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: Nonclinical studies assessing general, reproductive, and developmental toxicity","volume":"36","author":"Wise","year":"2018","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.reprotox.2010.09.001","article-title":"Evaluation of the intramuscular administration of Cervarix\u2122 vaccine on fertility, pre-and post-natal development in rats","volume":"31","author":"Segal","year":"2011","journal-title":"Reprod. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40265-014-0255-z","article-title":"Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil\u00ae): A review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1099\/0022-1317-80-9-2471","article-title":"A recombinant human papillomavirus (HPV) type 16 L1\u2013vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles","volume":"80","author":"Marais","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.intimp.2016.10.019","article-title":"Flow cytometric analysis of T lymphocyte proliferation in vivo by EdU incorporation","volume":"41","author":"Sun","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/bdrb.20174","article-title":"Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats","volume":"83","author":"Wolf","year":"2008","journal-title":"Birth Defects Res. Part B Dev. Reprod. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1800380","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800380","article-title":"A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017","volume":"24","author":"Ward","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/imcb.12650","article-title":"The crossroads: Divergent roles of virus-specific CD4+ T lymphocytes in determining the outcome for human papillomavirus infection","volume":"101","author":"Kelleher","year":"2023","journal-title":"Immunol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pasupuleti, D., Bagwe, P., Ferguson, A., NUddin, M., Souza, M.J.D., and Zughaier, S.M. (2024). Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay. Vaccines, 12.","DOI":"10.3390\/vaccines12091049"},{"key":"ref_32","first-page":"1003","article-title":"Potentiation of human papilloma vaccine candidate using naloxone\/alum mixture as an adjuvant: Increasing immunogenicity of HPV-16E7d vaccine","volume":"19","author":"Yasaghi","year":"2016","journal-title":"Iran J. Basic Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01113","DOI":"10.1016\/j.heliyon.2018.e01113","article-title":"Efficient protection of mice from influenza A\/H1N1pdm09 virus challenge infection via high avidity serum antibodies induced by booster immunizations with inactivated whole virus vaccine","volume":"5","author":"Sato","year":"2019","journal-title":"Heliyon"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41598-019-41171-8","article-title":"Evaluation of a new lymphocyte proliferation assay based on cyclic voltammetry; an alternative method","volume":"9","author":"Nikbakht","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/376505","article-title":"Cellular Immune Responses to Human Papillomavirus (HPV)-16 L1 in Healthy Volunteers Immunized with Recombinant HPV-16 L1 Virus-Like Particles","volume":"188","author":"Pinto","year":"2023","journal-title":"Infect Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"He, Y. (2014). Vaccine adjuvant informatics: From data integration and analysis to rational vaccine adjuvant design. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00032"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.molimm.2010.03.010","article-title":"IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines In Vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo","volume":"47","author":"Serre","year":"2010","journal-title":"Mol. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, J., Li, X., Dong, J., Wei, J., Guo, X., Wang, G., Xu, M., and Zhao, A. (2024). Enhanced Immune Responses in Mice by Combining the Mpox Virus B6R-Protein and Aluminum Hydroxide-CpG Vaccine Adjuvants. Vaccines, 12.","DOI":"10.3390\/vaccines12070776"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum. Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/66\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:45:08Z","timestamp":1767627908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010066"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010066","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}